Xiangxue Pharma Announces TAEST16001 Injection Listed as Breakthrough Therapy by CDE for HLA-A*02:01+/NY-ESO-1+ Soft Tissue Sarcoma

Xiangxue Pharmaceutical: TAEST16001 Injection, submitted by its subsidiary Xiangxue Life Sciences, has been included in the list of breakthrough therapies by the Center for Drug Evaluation of the National Medical Products Administration. It is intended for the treatment of soft tissue sarcoma with HLA-A*02:01 tissue genotype and positive expression of tumor antigen NY-ESO-1.